Immune Checkpoint Markers

Outstanding PD-L1 Antibody from GeneTex for your Research

Increasing knowledge of how cancer cells escape immune destruction has significantly driven the evolution of cancer immunotherapy. In particular, studies describing how different immune checkpoints, including the PD-1 and CTLA-4 pathways, function to attenuate T cell antitumor activity have revealed novel opportunities for therapeutic intervention. Researchers have made promising strides in inhibiting these checkpoints to unleash the T cells’ tumor-killing potential. Given that both radiotherapy and chemotherapy can also mobilize antitumor T cells, there is great excitement that checkpoint inhibition and other immunomodulatory approaches can be combined with conventional modalities to maximize clinical outcomes for a number of malignancies.

Our partner GeneTex proudly provides an outstanding PD-L1 antibody for your research.

 

PD-L1 antibody

 

PD-L1 antibodies recognize programmed death-ligand 1 (PD-L1) protein, also known as B7 homolog 1 (B7-H1) and cluster of differentiation 274 (CD274) protein. PD-L1 is found on various cancer cells and transduces immunosuppressive signals by binding to the programmed cell death protein 1 (PD-1) on effector T cells, thereby diminishing immune system attacks on malignant cells. Blocking the interaction between PD-L1 and PD-1 with PD-L1 antibodies is generating great clinical interest as a mode of immunotherapy against a number of cancers.

The much-cited PD-L1 antibody from GeneTex (Art. Nr. GTX104763), used at 1:1000 for IHC, is highly specific and sensitive, as shown by knockout/knockdown validation.

 

KO/KD-Validated

IHC

Target Specificity

 

 

Further GeneTex antibodies for your immune checkpoint research:

 

IDO1 antibody (GTX113753)

Galectin 3 antibody (GTX113486)

HMGB1 antibody (GTX101277)

GeneTex offers 10 µl antibody samples of these products for trial.

 

More information on Immune Checkpoint Markers:

>> News: Adaptive Immunity - HLA-G antibody panel for flow cytometry

>> Journal Club: The RANK Pathway as an Immune Modulator in Breast Cancer

>> Journal Club: HLA-G and HLA-E Immune Checkpoints Are Widely Expressedin Ewing Sarcoma

 

16.12.2021

Other News

Immune Checkpoint markers

Immune Checkpoint ma...

Antibodies for Immunohistochemistry

EbbaBiotech Optotracers

Fluorescent Optotrac...

Visualize protein, carbohydrate and bacterial structures

RecombiMAb™

RecombiMAb™

Recombinant Monoclonal Antibodies from Bio X Cell

analytica 2022 | 21.-24. June | Munich Tradefair

analytica 2022

21.-24. June | Munich Tradefair

Webinars Spring 2022

Webinars Spring 2022

3D cell culture and AI designed antibodies